YIDU TECH (02158) has repurchased a total of 32 times this year, spending more than 2.2 billion Hong Kong dollars, and its clinical AI products have been validated and implemented.

On March 18th, YIDU TECH (02158) once again disclosed its share repurchase actions, spending over 6.5 million Hong Kong dollars to repurchase company shares on the same day. According to the company's announcement, the company has implemented a total of 32 repurchases since the beginning of this year, with a total investment of over 220 million Hong Kong dollars. As of now, the company's treasury stock ratio has increased to about 4.5% of the total share capital, setting a new record for the company and placing it at the "top" of the pyramid in terms of the proportion of treasury stock among Hong Kong listed companies. In market practice, continuous share repurchases by listed companies are often seen as a signal to the market that the stock price is undervalued. The increase in treasury stock ratio also provides a more flexible mechanism for the company to conduct future equity incentives, promote mergers and acquisitions, and other capital operations. Since February 26th, YIDU TECH has conducted repurchases for 15 consecutive trading days. Among small and medium-sized companies, its repurchase frequency and cumulative investment amount are quite prominent. Analysts believe that these operations reflect the management's judgment that the current stock price does not fully reflect the intrinsic value of the company. It is worth noting that the company has recently made substantial progress in advancing its AI medical products. In terms of news, the clinical evidence-based intelligent system "Yidu Zhi Xun" developed by YIDU TECH has been clinically validated at multiple medical institutions, including the Cancer Prevention and Control Center of Sun Yat-sen University, covering 15 tumor types such as lung cancer, breast cancer, liver cancer, and colorectal cancer. After completing an internal test involving over 6,000 medical professionals, the "Yidu Zhi Xun" app version is about to be launched, providing clinical professionals with a professional assistance tool. In terms of international business expansion, YIDU TECH recently signed a strategic cooperation agreement with Guangxi Medical University and related institutions to jointly establish the Guangxi Medical Artificial Intelligence Research Institute, promoting the application exploration of "artificial intelligence + medical health" in Guangxi and the ASEAN region. This cooperation aims to promote the landing of the company's existing technological achievements in Guangxi and carry out technology output and application cooperation in the ASEAN region. From recent developments, the company is not only continuing its share repurchases in the capital market, but also intensifying the clinical validation of its AI products and international cooperation efforts. This combination of actions has attracted considerable attention in the Hong Kong technology sector, with the market having high expectations for the company's future business implementation and value realization.